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KLK3 SNP–SNP interactions
for prediction of prostate cancer
aggressiveness
Hui‑Yi Lin1*, Po‑Yu Huang2, Chia‑Ho Cheng3, Heng‑Yuan Tung1, Zhide Fang1,
Anders E. Berglund3, Ann Chen3, Jennifer French‑Kwawu1, Darian Harris1, Julio Pow‑Sang4,
Kosj Yamoah5, John L. Cleveland6, Shivanshu Awasthi7, Robert J. Rounbehler6, Travis Gerke7,
Jasreman Dhillon8, Rosalind Eeles9,10, Zsofia Kote‑Jarai9, Kenneth Muir11,12, UKGPCS
collaborators*, Johanna Schleutker13,14, Nora Pashayan15,16,17, APCB (Australian Prostate
Cancer BioResource)*, David E. Neal18,19, Sune F. Nielsen20,21, Børge G. Nordestgaard20,21,
Henrik Gronberg22, Fredrik Wiklund22, Graham G. Giles23,24,25, Christopher A. Haiman26,
Ruth C. Travis27, Janet L. Stanford28,29, Adam S. Kibel30, Cezary Cybulski31,
Kay‑Tee Khaw32, Christiane Maier33, Stephen N. Thibodeau34, Manuel R. Teixeira35,36,
Lisa Cannon‑Albright37,38, Hermann Brenner39,40,41, Radka Kaneva42, Hardev Pandha43, The
PRACTICAL consortium*, Srilakshmi Srinivasan44,45, Judith Clements44,45, Jyotsna Batra44,45 &
Jong Y. Park7
Risk classification for prostate cancer (PCa) aggressiveness and underlying mechanisms remain
inadequate. Interactions between single nucleotide polymorphisms (SNPs) may provide a solution
to fill these gaps. To identify SNP–SNP interactions in the four pathways (the angiogenesis-,
mitochondria-, miRNA-, and androgen metabolism-related pathways) associated with PCa
aggressiveness, we tested 8587 SNPs for 20,729 cases from the PCa consortium. We identified 3
KLK3 SNPs, and 1083 (P < 3.5 × 10–9) and 3145 (P < 1 × 10–5) SNP–SNP interaction pairs significantly
associated with PCa aggressiveness. These SNP pairs associated with PCa aggressiveness were more
significant than each of their constituent SNP individual effects. The majority (98.6%) of the 3145
pairs involved KLK3. The 3 most common gene–gene interactions were KLK3-COL4A1:COL4A2, KLK3CDH13, and KLK3-TGFBR3. Predictions from the SNP interaction-based polygenic risk score based on
24 SNP pairs are promising. The prevalence of PCa aggressiveness was 49.8%, 21.9%, and 7.0% for
the PCa cases from our cohort with the top 1%, middle 50%, and bottom 1% risk profiles. Potential
biological functions of the identified KLK3 SNP–SNP interactions were supported by gene expression
and protein–protein interaction results. Our findings suggest KLK3 SNP interactions may play an
important role in PCa aggressiveness.
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Prostate cancer (PCa) accounts for over 10% of all cancer-related deaths, making it the second leading cause of
cancer-related deaths among American men in 20211. Because of the substantial clinical heterogeneity of this
disease, physicians often have difficulty distinguishing at the time of diagnosis between patients who will develop
indolent tumors and those who will develop aggressive PCa2. For PCa patients considered to be at a low risk for
aggressive PCa, conservative management and treatment are presently recommended. However, ~ 20% of PCa
patients who are classified as a low risk using the known classification features (such as prostate specific antigen
[PSA], tumor stage, and Gleason score) still die during conservative t reatment3. This demonstrates an unmet
need to identify better biomarkers for predicting PCa aggressiveness.
Genetic association studies have primarily focused on the effects of individual single-nucleotide polymorphisms (SNPs), which are insufficient to explain the complexity of disease susceptibility. However, the majority
of SNPs identified by genome-wide association studies (GWAS) are for PCa risk, and only a few are for PCa
progression. In fact, only 41 SNPs have been suggested to be associated with PCa progression related phenotypes
(such as aggressiveness, early-onset, and PCa survival) in GWAS from the GWAS catalog4. These 41 SNPs are
located across 53 genes (some are intergenic SNPs), including KLK3, ADGRG1, ARHGAP6, CASC8, and TCF44.
We and others reported several polygenic risk scores (PRS) for PCa risk based on multiple individual SNP
effects5–7, but the prediction model of PCa aggressiveness remains underdeveloped.
It has been established that gene–gene/SNP–SNP interactions may play a larger role in the causality of complex diseases8. Although SNP–SNP interactions have received more attention in the past decade, few have been
validated, and most are without known biological functions. The limited SNP–SNP interaction findings may be
due to insufficient statistical methods. The conventional approach for testing 2-way SNP–SNP interactions is
the Additive–Additive full interaction (AA_Full) approach, the full or hierarchical interaction model (2 main
effects + interaction) with the additive SNP inherited mode. AA_Full is the most complicated interaction pattern with the 9 distinct risk-groups, so a large sample size will be needed for detecting this complicated pattern.
Using AA_Full to detect SNP–SNP interactions tends to lead to false-negative findings because it only tested
one complicated interaction pattern. In order to overcome this issue, we developed two statistical methods:
SNP Interaction Pattern Identifier (SIPI) and Additive-Additive 9 Interaction-Model approach (AA9int)9,10.
The AA9int approach, which treats all SNPs in an additive inheritance mode, tests nine interaction patterns
of pairwise SNP–SNP interactions associated with an outcome10. The SIPI approach is an extended version of
AA9int and tests 45 biologically meaningful SNP–SNP interaction patterns by considering three SNP inheritance
modes (additive, dominant and recessive)9.
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Figure 1.  Selection procedure of SNPs and SNP–SNP interaction pairs associated with prostate cancer
aggressiveness. aP < 5.8 × 10–6 is based on Bonferroni correction; candidate SNPs for interaction analyses:
5345 SNPs; 3 SNPs are rs17632542, rs62113212, and rs2569735 in KLK3. bFor SNP interactions, the 2-stage
AA9int + SIPI was applied. Using AA9int, 66,619 pairs were selected with a P < 10–3 in the discovery set, then
66,321 pairs were selected in the second stage using the SIPI approach. SIPI was applied for the validation
and combined set analyses. AA9int Additive–Additive 9 interaction-model approach, p_individual p-value of
individual SNP effect, p_int p-value of interaction, SIPI SNP interaction pattern identifier, SNP single nucleotide
polymorphism. cAA_Full Additive–additive full interaction model.

Accumulating evidence suggests that interplay among angiogenesis-, mitochondria-, miRNA-, and androgen
metabolism-related pathways may play a critical role in P
 Ca11–14. Androgen expression, epigenetic factors, and
oxygen levels in the tumor microenvironment regulate angiogenesis, which leads to metastatic PCa15,16. Therapies targeting both angiogenesis and androgen for recurrent PCa patients could increase survival rates17. These
findings suggest that the relationship between androgen and angiogenesis and how their interaction can impact
on PCa aggressiveness. Genes involved in androgen metabolism pathways also lead to oncogenic metabolic phenotypes, such as mitochondrial respiration and cell proliferation, in PCa cells. In addition, androgen repression
in PCa cells decreases mitochondrial activity18. We and others have reported that miRNAs (such as miR-221,
miR-222, and miR-155) are involved in regulating various aspects of angiogenesis and PCa p
 rogression12,19. This
evidence suggests that the interplay among genes in these 4 pathways may impact PCa aggressiveness.
This study was inspired by the shortage of SNP findings associated with PCa aggressiveness. Only a small
number of SNPs were identified to be associated with PCa aggressiveness, and there is no PRS for PCa aggressiveness. In addition, most of the PRS is based on the sum of several individual SNP effects without considering
SNP–SNP interactions. Because of the inspiration, this study’s objective is to identify SNP–SNP/gene–gene
interactions and to build a SNP-interaction based PRS ( SNPint-PRS) associated with PCa aggressiveness. These
SNPs were selected based on genes in the four PCa biological related pathways (angiogenesis, mitochondria,
miRNA, and androgen metabolism).

Results

Individual SNP effects. The process of identifying the significant effects of individual SNPs and SNP–SNP
interactions associated with PCa aggressiveness is described in Fig. 1. The individual SNP effect analyses were
performed for both the discovery and validation sets. The criterion of a P < 0.001 was applied in both the discovery and validation sets to declare validated results. As shown in Table 1, there were 3 KLK3 SNPs (rs17632542,
rs62113212, and rs2569735) with a P < 0.001 in both study sets, and all of these three SNPs reached the Bonferroni significance level (P < 1.9 × 10–6) in the combined set. The best inheritance mode for these 3 SNPs was an
additive mode. PCa cases with the minor G allele in rs17632542 tended to have a higher risk of PCa aggressiveness (odds ratio [OR]= 1.45; P = 1.7 × 10–13). Cases with the minor A allele in rs62113212 (OR per A allele
1.45; P = 2.1 × 10–13) and rs2569735 (OR= 1.23; P = 1.4 × 10–8) also had a higher risk of PCa aggressiveness. The
relationships for these KLK3 SNPs are shown in Supplementary Fig. S1. rs17632542 and rs62113212 were highly
correlated (linkage disequilibrium [LD] r 2 = 0.98), and the association between rs17632542 and rs2569735 was
moderate (LD r2 = 0.42).
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Combined set
SNPa

Min < Maj (MAF)

P valueb

OR (95% CI)b

–13

1.45 (1.31, 1.60)

Discovery set

Validation set

P valueb

P valueb

Genes

Add

5.8 × 10

–8

1.3 × 10–7

KLK3

Mode

rs17632542

G < A (0.06)

1.7 × 10

rs62113212

A < G (0.06)

2.1 × 10–13

1.45 (1.31, 1.59)

Add

1.4 × 10–7

7.3 × 10–8

KLK3

rs2569735

A < G (0.12)

1.4 × 10–8

1.23 (1.14, 1.32)

Add

9.3 × 10–5

2.7 × 10–5

KLK3

rs1058205

G < A (0.15)

5.0 × 10–7

1.18 (1.11, 1.26)

Add

1.6 × 10–3

5.3 × 10–5

KLK3

rs174776

A < G (0.11)

4.9 × 10–6

1.19 (1.10, 1.28)

Add

2.3 × 10–3

4.7 × 10–4

KLK3

rs266876

G < A (0.24)

1.2 × 10–5

1.13 (1.07, 1.20)

Add

2.0 × 10–2

8.1 × 10–5

KLK3

rs2271095

G < A (0.35)

1.7 × 10–5

0.90 (0.85, 0.94)

Add

3.1 × 10–3

2.0 × 10–3

KLK3

rs4802755

A < G (0.46)

2.0 × 10–5

1.11 (1.06, 1.17)

Add

2.0 × 10–2

8.0 × 10–5

KLK3

rs7446

A < G (0.31)

2.4 × 10–5

1.16 (1.08, 1.24)

Dom

3.9 × 10–2

9.1 × 10–5

KPNA3

rs6998

A < G (0.37)

6.3 × 10–5

0.90 (0.86, 0.95)

Add

9.2 × 10–3

2.3 × 10–3

KLK3

rs4802754

A < G (0.29)

1.8 × 10–4

0.90 (0.86, 0.95)

Add

1.9 × 10–3

3.0 × 10–2

KLK3

rs2361634

G < A (0.07)

3.5 × 10–4

1.12 (1.05, 1.20)

Add

2.9 × 10–2

5.0 × 10–3

AR

Table 1.  Individual SNP effects associated with prostate cancer aggressiveness. add additive, dom dominant,
MAF minor allele frequency, maj major allele, min minor allele, rec recessive, SNP single nucleotide
polymorphism. a First 3 SNPs are validated SNPs (discovery p < 1 × 10–3 and validation p < 1 × 10–3). Except
rs62113212, other SNPs are the hub SNPs in the 11 clusters. Linkage disequilibrium: r 2(rs17632542,
rs62113212) = 0.98. b All models adjusted for study sites and six principal components for population
stratification; OR odds ratio, CI confidence interval.

SNP–SNP interactions. By applying the AA_Full approach for 1.4 × 107 SNP pairs associated with PCa
aggressiveness, only one pair (rs390993 + rs473640 in RIPK2 and NOS1) qualified the selection criteria: P < 0.001
in the discovery, validation, and combined sets (Fig. 1). Using the AA_Full approach, 13,127 SNP pairs had
P < 0.001 in the discovery set. Among them, only 1 pair (rs390993 + rs473640 in RIPK2 and NOS1) satisfied the
validation criteria. The interaction p-values of rs390993 + rs473640 were 4.5 × 10–5, 9.2 × 10–4, and 2.8 × 10–7 for
the discovery, validation, and combined sets. The interaction patterns for this SNP pair were shown in Supplementary Fig. S2.
We applied the 2-stage Additive–Additive 9 interaction model approach and SNP Interaction Pattern Identifier (AA9int + SIPI) approach to search for SNP–SNP interactions associated with PCa aggressiveness in the
discovery set to reduce computation burden and maintain prediction power (Fig. 1). When testing 1.4 × 107
SNP pairs using the AA9int approach, 66,619 pairs had a P < 0.001. Then, we applied SIPI for further interaction analyses and found 66,321 pairs with a P < 0.001 in the discovery set, of which 11,449 pairs were validated.
In the combined set, 9492 pairs were promising because they had a P < 1 × 10–5, which was the criterion we
selected based on the plot of the − log10 P values in Supplementary Fig. S3. Further, 3795 of these SNP pairs
also met the stringent Bonferroni criterion (P < 3.5 × 10–9). Among 3795 SNP pairs, 1083 pairs’ interaction had
a lower p-value than their 2 constituent SNP effects. Of the 9492 promising pairs, 3144 SNP interaction pairs
were more significant than their constituent SNPs. All 1083 SNP pairs and 98.6% of the top 3144 promising
pairs associated with PCa aggressiveness were involved with KLK3 SNPs. Among the top 3144 SNP pairs associated with PCa aggressiveness, 4 KLK3 clusters contributed 91% of these pairs (n = 2856/3144). These 4 KLK3
clusters were rs17632542 (769 pairs), rs2569735 (1132 pairs), rs1058205 (601 pairs), and rs174776 (350 pairs).
The most significant 5 SNP pairs within these 4 KLK3 clusters are listed in Table 2, and the top non-KLK3 pairs
with P < 1 × 10–6 are listed in Supplementary Table S1.
The most significant SNP pair was rs4783709 + rs17632542 in CYB5B: LOC105371325 and KLK3, with a P
value of 4.6 × 10–16 in the combined set, 2.2 × 10–8 in the discovery set, and 3.1 × 10–9 in the validation set. As
shown in Table 2 and Fig. 2A, the identified interaction pattern for the rs4783709 + rs17632542 SNP pair in the
discovery, validation, and combined sets was AA_int_ro, which indicates the additive–additive interaction-only
pattern with the reverse and original mode for the first and second SNPs, respectively. PCa cases with the major
allele G in rs4783709 and the minor allele G in rs17632542 in KLK3 had a higher risk of PCa aggressiveness
(P = 4.6 × 10–16; OR= 1.29 per one unit of the G × G allele with a coding of 0, 1, 2 for each allele) in the combined
set. In the SNP pair of rs4783709 + rs17632542, the prevalence of PCa aggressiveness was 20%, 26%, 33%, and
41% for PCa cases with the genotype combinations of AA + AA, GA + AG, GG/AG, and GG + GG, respectively,
with a respective coding of 0, 1, 2, and 4. The rs2569735 + rs4802754 (2 KLK3 SNP interactions) pair in the
combined set (Fig. 2B) had a DD_int_or pattern, which indicates a dominant–dominant interaction-only pattern
with the original mode for SNP1 and reverse mode for SNP2. The PCa cases with the GA/AA + GG genotype in
rs2569735 + rs4802754, respectively, had a higher risk of PCa aggressiveness (OR= 1.36; P = 4.2 × 10–11) compared
with the group with other genotypes for this SNP pair. As shown in Fig. 2B, the prevalence of PCa aggressiveness
was 23% for the entire cohort and 27–32% for the GA/AA + GG group in the SNP pair of rs2569735 + rs4802754.
Although the validation set had a different interaction pattern of AA_int_or compared with the discovery and
combined sets, their trends were similar.
The majority of the identified SNP interactions are interaction-only models with only 1 interaction term in
each model; only a few SNP interactions had a complicated model with > 1 terms (such as M1_int or M2_int).
Some examples of these complicated interaction patterns are listed in Table 2 and Supplementary Fig. S4. The
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SNP1

SNP2

Interaction
pattern
labela

Pattern
details

SNP1
Min < Maj
(MAF)

SNP2
Min < Maj
(MAF)

Combined
P valueb

OR (95%
CI)b

Dis. P valueb Val. P valueb Gene1

G < A (0.06)

–16

4.6 × 10

1.29 (1.21,
1.37)

2.2 × 10

Gene2

3.1 × 10

CYB5B:
LOC105371325

KLK3

rs4783709

rs17632542

AA_int_ro

SNP1xSNP2
(G,G)

rs2050143

rs17632542

AA_int_ro

SNP1xSNP2
(A,G)

G < A (0.28)

G < A (0.06)

6.7 × 10–16

1.29 (1.21,
1.37)

3.9 × 10–10

1.6 × 10–8

PDGFB

KLK3

rs16837637

rs17632542

RD_int_ro

(GG/
GA + AG/
GG) vs.
others

A < G (0.39)

G < A (0.06)

6.8 × 10–16

1.57 (1.41,
1.75)

1.1 × 10–7

5.5 × 10–10

NRP2

KLK3

rs9301460

rs17632542

AA_int_ro

SNP1xSNP2
(G,G)

A < G (0.38)

G < A (0.06)

1.2 × 10–15

1.31 (1.23,
1.40)

9.0 × 10–10

1.6 × 10–8

COL4A2:COL4A2AS1

KLK3

rs7196117

rs17632542

RD_int_rr

(AA/
AG + AA) vs. G < A (0.19)
others

G < A (0.06)

1.9 × 10–15

0.69 (0.63,
0.76)

1.0 × 10–8

2.3 × 10–8

LOC105371286:
LOC105371287

KLK3

rs17632542

rs2569735

DD_int_oo

(AG/
GG + GA/
AA) vs.
others

G < A (0.06)

A < G (0.12)

5.2 × 10–13

1.46 (1.32,
1.62)

5.3 × 10–8

7.2 × 10–8

KLK3

KLK3

rs7613553

rs2569735

AA_int_ro

SNP1xSNP2
(C,A)

A < C (0.44)

A < G (0.121) 7.2 × 10–12

1.20 (1.14,
1.26)

3.0 × 10–7

3.2 × 10–6

RARB

KLK3

rs2292185

rs2569735

AA_int_ro

SNP1xSNP2
(G,A)

A < G (0.39)

A < G (0.12)

3.6 × 10–11

1.15 (1.10,
1.20)

5.5 × 10–6

9.3 × 10–7

KLK3

KLK3

A < G (0.12)

A < G (0.29)

4.2 × 10–11

1.36 (1.24,
1.49)

2.6 × 10–6

1.5 × 10–6

KLK3

KLK3

A < G (0.31)

–8

–9

rs2569735

rs4802754

DD_int_or

(GA + AA/
GG) vs.
others

rs2569735

rs2766535

AA_M2_
int_r2

SNP2 (G)
SNP1xSNP2
(A,G)

A < G (0.12)

A < G (0.45)

0.001
5.3 × 10–11

0.92 (0.87,
0.97)
1.20 (1.13,
1.26)

3.4 × 10–7

5.2 × 10–6

KLK3

FKBP5

rs1058205

rs17632542

DD_int_oo

(AG/
GG + AG/
GG) vs.
others

G < A (0.15)

G < A (0.06)

5.9 × 10–13

1.46 (1.32,
1.61)

1.3 × 10–7

1.7 × 10–7

KLK3

KLK3

rs1058205

rs2361634

AA_int_rr

SNP1xSNP2
(A,A)

G < A (0.15)

G < A (0.07)

5.2 × 10–10

0.92 (0.90,
0.95)

1.2 × 10–4

7.1 × 10–7

KLK3

AR

rs385037

rs1058205

AA_int_ro

SNP1xSNP2
(A,G)

G < A (0.41)

G < A (0.15)

1.5 × 10–9

1.15 (1.10,
1.20)

3.8 × 10–5

7.0 × 10–6

RAB20

KLK3

rs7613553

rs1058205

AA_int_ro

SNP1xSNP2
(C,G)

A < C (0.44)

G < A (0.15)

1.5 × 10–9

1.15 (1.10,
1.21)

1.6 × 10–5

1.6 × 10–5

RARB

KLK3

rs2274545

rs1058205

AA_int_ro

SNP1xSNP2
(A,G)

C < A (0.28)

G < A (0.15)

2.0 × 10–9

1.13 (1.09,
1.18)

7.4 × 10–5

4.7 × 10–6

COL4A2

KLK3

G < A (0.06)

1.6 × 10–14

0.68 (0.61,
0.75)

3.0 × 10–8

6.3 × 10–8

KLK3

KLK3

rs174776

rs17632542

RD_int_rr

(GG/
GA + AA) vs. A < G (0.11)
others

rs10520259

rs174776

AA_M1_
int_o1

SNP1(A)
SNP1xSNP2
(A,A)

A < G (0.28)

A < G (0.11)

0.001
1.2 × 10–9

0.91 (0.86,
0.96)
1.31 (1.20,
1.43)

5.7 × 10–5

6.4 × 10–4

HAND2

KLK3

rs1250240

rs174776

DR_int_ro

(GG + AA)
vs. others

A < G (0.26)

A < G (0.11)

2.4 × 10–9

2.96 (2.07,
4.24)

5.9 × 10–5

1.0 × 10–5

FN1

KLK3

A < G (0.11)

G < A (0.07)

4.3 × 10–9

0.92 (0.90,
0.95)

1.1 × 10–4

8.9 × 10–6

KLK3

AR

A < G (0.11)

A < G (0.12)

7.9 × 10–9

1.21 (1.14,
1.29)

3.1 × 10–5

4.0 × 10–5

KLK3

KLK3

rs174776

rs2361634

AA_int_rr

SNP1xSNP2
(G,A)

rs174776

rs2569735

AA_int_oo

SNP1xSNP2
(A,A)

Table 2.  Top 5 pairs for the four KLK3 clusters of rs2569735, rs17632542, rs1058205, and rs174776 associated
with prostate cancer aggressiveness. CI confidence interval, Dis discovery set, MAF minor allele frequency,
Maj major allele, Min minor allele, OR odds ratio, Val validation set. a SIPI pattern interpretation: The first 2
letters represent inheritance modes of the first SNP (or SNP1) and the 2nd SNPs (or SNP2); mode (A, additive
mode; D, dominant mode; R, recessive mode; “(SNP1 mode)(SNP2 mode)_int_(SNP1 code)(SNP2 code)” is
for interaction-only pattern; “Mϕ_int_”, interaction plus one main effect of SNPϕ; SNP code (o, original coding
based on the minor allele; r, reverse coding; o1: original coding for SNP1 (SNP2 with original coding); r2:
reverse coding of SNP2 (SNP1 with original coding). b For verified SNP pairs with P < 1 × 10–5 in the combined
set and p_interaction < p_individual; all models adjusted for study site and first six principal components.

interaction pattern for the SNP pair of rs10520259 in HAND2 + rs174776 in KLK3, which was associated with
PCa aggressiveness, was AA_M1_int_o1. This is an additive–additive model plus the main effect of rs10520259
(rs10520259 + rs10520259 × rs174776) with an original mode for both SNPs. Among PCa cases with the rs174776
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Figure 2.  Selected SNP–SNP interactions associated with prostate cancer aggressiveness. PCa aggr (n):
prevalence of prostate cancer aggressiveness (sample size in the genotype combination); SNP–SNP Interaction
Pattern: “(SNP1 mode)(SNP2 mode)_int_(SNP1 code)(SNP2 code)”; OR of PCa aggressiveness adjusted for
study sites and six principal components for population stratification. The darker color indicates a higher chance
of prostate cancer aggressiveness. A additive inheritance modes, aggr aggressiveness, D dominant inheritance
modes, o original coding based on the minor allele, OR odds ratio, PCa prostate cancer, R recessive inheritance
modes, r reverse code direction, SNP single-nucleotide polymorphism. These heat tables were generated using
the plot3by3 function in the SIPI R package.
GG genotype, an A allele of rs10520259 was associated with a lower risk of PCa aggressiveness (OR= 0.91;
P = 0.001). For PCa cases with the rs174776 GA/AA genotypes, the rs10520259 A allele had an opposite effect
(OR= 1.31; P = 1.2 × 10–9).

Examples of SNP–SNP interaction pairs with a large effect size. There were 8 significant SNP pairs
with a large effect size (OR ≥ 2.00) associated with PCa aggressiveness for the binary-mode interaction models,
including the DD_, DR_, RD_, and RR_ models. To identify a large effect size, different OR criteria should be
applied for the binary-mode interaction models and AA models because they have different coding scales: (0,
1) for the binary-mode interaction models and (0, 1, 2, and 4) for the AA models. For AA models, there were
20 pairs with OR ≥ 1.3, and the top 5 pairs with OR ≥ 1.35 are shown in Table 3. All 5 of these pairs are involved
with KLK3 rs17632542.
As shown in Table 3, the pair with the largest effect size was rs3775202 + rs174776 with the RR_int_oo pattern,
a recessive–recessive interaction-only pattern with an original mode. The interaction pattern in the discovery
set was not the same but had a similar trend. Though the prevalence of aggressive PCa for the entire cohort was
23% (Fig. 3A), the prevalence among the cases with the AA + AA genotype in rs3775202 + rs174776 in VEGFC
and KLK3 was 54% (OR= 4.12 for AA + AA genotype compared with others; P = 5.9 × 10–7) in the combined
set. Another example of an SNP pair with a large effect size was rs1250240 + rs174776 (FN1 + KLK3) with the
DR_int_ro pattern, a dominant–recessive interaction with a reverse mode in the validation and combined sets
(Fig. 3B). PCa cases with the GG + AA genotype in rs1250240 + rs174776 had a higher risk of being aggressive
(OR= 3.22 and 2.96 in the validation and combined sets, respectively). The interaction pattern of this pair was
similar in the discovery set. As shown in Fig. 3A,B, PCa prevalence for a specific SNP genotype would be altered

Scientific Reports |
Vol:.(1234567890)

(2021) 11:9264 |

https://doi.org/10.1038/s41598-021-85169-7

6

www.nature.com/scientificreports/

SNP1

SNP2

Interaction
pattern
labela

Pattern
details

SNP1
Min < Maj
(MAF)

SNP2
Min < Maj
(MAF)

Combined
P valueb

OR (95%
CI)b

Dis. P
valueb

Val. P
valueb

Gene1

Gene2

2.3 × 10

VEGFC

KLK3

rs3775202

rs174776

RR_int_oo

(AA + AA)
vs. others

A < G (0.49)

A < G (0.11)

5.9 × 10

4.12 (2.36,
7.19)

rs2317676

rs7802277

DR_M2_
int_o2

(AA + AA)
(AG/
G < A (0.07)
GG + AA) vs.
others

A < G (0.14)

8.3 × 10–4
6.5 × 10–5

0.62 (0.47,
0.82)
3.13 (1.79,
5.47)

9.2 × 10–4

9.2 × 10–4

ITGB3

MTCYBP42

rs1250240

rs174776

DR_int_ro

(GG + AA)
vs. others

A < G (0.26)

A < G (0.11)

2.4 × 10–9

2.96 (2.07,
4.24)

5.8 × 10–5

1.0 × 10–5

FN1

KLK3

rs7224135

rs174776

DR_int_ro

(GG + AA)
vs. others

A < G (0.42)

A < G (0.11)

9.5 × 10–7

2.88 (1.89,
4.40)

7.0 × 10–4

3.8 × 10–4

CAVIN1

KLK3

rs2075756

rs174776

DR_int_ro

(GG + AA)
vs. others

A < G (0.28)

A < G (0.11)

4.1 × 10–8

2.74 (1.91,
3.92)

1.8 × 10–4

4.8 × 10–5

TRIP6

KLK3

1.6 × 10–4

4.4 × 10–4

LRRK2

KLK3

–7

–4

1.2 × 10

–4

rs10467147

rs174776

DR_int_ro

(GG + AA)
vs. others

A < G (0.33)

A < G (0.11)

4.0 × 10–6

2.50 (1.69,
3.69)

rs1980499

rs174776

RR_int_ro

(AA/
AG + AA) vs. G < A (0.49)
others

A < G (0.11)

1.1 × 10–6

2.19 (1.60,
3.00)

1.3 × 10–4

4.5 × 10–5

BMP2

KLK3

rs2224524

rs174776

RR_int_ro

(GG/
GA + AA) vs. A < G (0.43)
others

A < G (0.11)

3.3 × 10–6

2.01 (1.50,
2.69)

6.5 × 10–4

6.0 × 10–4

LOC107987087:
RASEF

KLK3

rs27650

rs17632542

AA_int_oo

SNP1xSNP2
(A,G)

G < A (0.06)

7.1 × 10–15

1.39 (1.28,
1.51)

3.0 × 10–9

1.9 × 10–8

RASGRF2

KLK3

A < G (0.48)

G < A (0.06)

6.5 × 10–15

1.36 (1.26,
1.46)

4.1 × 10–10

2.3 × 10–7

COL4A2:COL4A2AS1

KLK3

A < G (0.45)

rs414881

rs17632542

AA_int_oo

SNP1xSNP2
(A,G)

rs45631565

rs17632542

AA_int_oo

SNP1xSNP2
(A,G)

A < C (0.43)

G < A (0.06)

1.0 × 10–13

1.37 (1.26,
1.48)

7.7 × 10–9

1.3 × 10–6

FGFR2

KLK3

rs587409

rs17632542

AA_int_oo

SNP1xSNP2
(A,G)

A < G (0.47)

G < A (0.06)

2.3 × 10–15

1.38 (1.27,
1.49)

3.0 × 10–9

1.6 × 10–8

COL4A1

KLK3

rs9521801

rs17632542

AA_int_ro

SNP1xSNP2
(G,G)

A < G (0.5)

G < A (0.06)

4.5 × 10–15

1.36 (1.26,
1.46)

4.8 × 10–7

6.2 × 10–10

COL4A2

KLK3

Table 3.  SNP interaction pairs with a large effect size associated with prostate cancer aggressiveness. CI
confidence interval, Dis discovery set, MAF minor allele frequency, Maj major allele, Min minor allele, OR
odds ratio, Val validation set. a SIPI pattern interpretation: The first 2 letters represent inheritance modes of
the first SNP (or SNP1) and the 2nd SNPs (or SNP2); mode (A, additive mode; D, dominant mode; R, recessive
mode; “(SNP1 mode)(SNP2 mode)_int_(SNP1 code)(SNP2 code)” is for interaction-only pattern; “Mϕ_int_”,
interaction plus one main effect of SNPϕ; SNP code (o, original coding based on the minor allele; r, reverse
coding; o1: original coding for SNP1 (SNP2 with original coding); r2: reverse coding of SNP2 (SNP1 with
original coding). b For verified SNP pairs with P < 1 × 10–5 in the combined set and p_interaction < p_individual;
all models adjusted for study site and first six principal components.

when interacting with another SNP. Our results demonstrated that these SNP–SNP interaction patterns could
explain the PCa aggressiveness profile better than their constituent SNPs’ individual effects.
The pair with the second largest effect size was rs2317676 + rs7802277 (ITGB3 + MTCYBP42) with the DR_
M2_int_o2 pattern, a dominant–recessive interaction with the main effect of the second SNP (rs7802277) and
an original mode for both SNPs. As shown in Table 3 and Supplementary Fig. S4, the prevalence of aggressive
PCa was 44% for cases with the AG/GG + AA genotype (OR= 3.13; P = 6.5 × 10–5) and only 16% for cases with
the AA + AA genotype (OR= 0.62; P = 8.3 × 10–4), whereas the overall prevalence of aggressive PCa was 23% in
the combined set. In addition, there were 88 SNP pairs associated with PCa aggressiveness, with a medium effect
size (0.5 ≤ OR < 0.67 or 1.5 ≤ OR < 2) for SNP pairs with binary modes.

Non‑KLK3 SNP–SNP interaction pairs. Only 43 SNP pairs among the top 3144 SIPI identified pairs did

not involve KLK3, and 21 out of these 43 pairs were involved with rs7446 in KPNA3. The top 17 SNP pairs with a
P < 10–6 are listed in Supplementary Table S1. For the most significant SNP pair of rs2266967 (MAPK1) + rs7446
(KPNA3), PCa cases with the CA/AA + AG/AA genotype had a higher risk of PCa aggressiveness (OR= 1.21;
P = 3.6 × 10–8) compared to cases with other genotypes for this SNP pair. The SNP pair with the largest effect size
was rs2317676 (ITGB3) + rs7802277 (MTCYBP42).

SNP‑interaction PRS. Among the 3144 candidate pairs selected using the AA9int + SIPI approach, the
majority were in the 11 clusters identified in Supplementary Table S2; only 23 pairs were not involved in these
clusters. Some SNP pairs showed up in 2 clusters (such that SNPA–SNPB showed up in both cluster A and cluster
B), and so we dropped the duplicated pairs for model building. Nine of these 11 clusters were involved with
KLK3. By deleting the highly correlated SNP pairs and performing variable selection associated with PCa aggressiveness within each cluster (Supplementary Table S2), the number of candidate pairs for modeling was reduced
from 3144 to 96 pairs. The largest cluster was for rs2569735 in KLK3 with 1132 pairs, of which only 23 were
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Figure 3.  Selected SNP–SNP interactions with a large effect size associated with prostate cancer aggressiveness.
Note: PCa aggr (n): prevalence of prostate cancer aggressiveness (sample size in the genotype combination);
SNP–SNP Interaction Pattern: “(SNP1 mode)(SNP2 mode)_int_(SNP1 code)(SNP2 code)”; OR: odds ratio of
PCa aggressiveness adjusted for study sites and 6 principal components for population stratification. The darker
color indicates a higher risk of prostate cancer aggressiveness. A additive inheritance mode, aggr aggressiveness,
D dominant inheritance mode, o original coding based on the minor allele, OR odds ratio, PCa prostate cancer,
R recessive inheritance mode, r reverse code direction, SNP single-nucleotide polymorphism. These heat tables
were generated using the plot3by3 function in the SIPI R package.
low-correlated pairs (r < 0.7). After applying stepwise selection for pairs associated with PCa aggressiveness with
P < 0.1 as the selection criteria within a cluster, only 14 SNPs pairs were selected. The number of the selected pairs
for other clusters are listed in Supplementary Table S2. The candidate set for the multipair model was composed
of 96 pairs, including 76 selected pairs within the 11 clusters and 20 other SNP pairs.
We applied stepwise selection in logistic model for the SIPI selected pairs in the combined set. Using this
approach, 23 pairs and 12 pairs were selected based on a criterion of P < 0.01 and P < 1 × 10–5, respectively. We
evaluated the 24-pair model by adding 1 SNP pair (rs390993 + rs473640 in RIPK2 and NOS1) selected using
the AA_Full approach to the list of 23 SNP pairs. The 24-pair model comprised interactions between 42 SNPs
(Supplementary Table S3), and 9 of these pairs were involved with the KLK3 SNPs. The 12-pair model was made
of interactions between 24 total SNPs, and 3 pairs were involved with the KLK3 SNPs. Based on these 2 models,
we built the S NPint-PRS, then classified PCa cases into 7 groups based on their risk profiles (see Supplementary
Methods).
For the 24-pair model (Supplementary Table S4A), the OR of aggressiveness for PCa cases in the top 1%
high-risk group was 3.65 (95% CI= 2.71–4.91), and the OR for cases in the second highest risk group was 1.97
by using the 50% PCa cases with an average risk as to the reference group after adjusting for study site and the
6 principal components of population stratification as suggested by the PRACTICAL s tudy20. In addition, the
ORs of the cases with the lowest 1% and the 1–10% risk profile were 0.27 and 0.55, respectively. As shown in
Fig. 4, the prevalence of PCa aggressiveness for cases with the top 1%, middle 50%, and bottom 1% risk profiles
were 49.8%, 21.9%, and 7.0%, respectively. For the 12-pair model (Supplementary Table S4B), the ORs of PCa
aggressiveness for the top 1% and bottom 1% were 3.06 and 0.51, respectively.
For the individual-effect model, only rs17632542 was selected based on the stepwise selection with a significance level of 1 × 10–5 based on the 3 verified KLK3 SNPs in Table 1. As shown in Supplementary Table S5,
we compared the performance of these 2 S NPint-PRS with this individual-effect model using the area under the
receiver operator characteristics curve (AUC). The AUC values for the 24-pair model, 12-pair model and individual-effect model were 0.696, 0.687, and 0.668, respectively. The 24-pair model performed significantly better
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Figure 4.  Performance of the polygenic risk score of prostate cancer aggressiveness based on the 24 SNP
pairs. PCa prostate cancer, SNP single-nucleotide polymorphism. Mean and 95% confidence intervals of PCa
aggressiveness prevalence were shown.

than the individual-effect model with rs17632542 and the 12-pair model (AUC comparison P = 6.5 × 10–27 and
2.7 × 10–8, respectively). We also performed an internal validation using the bootstrap approach. The AUC’s 95%
confidence interval for the 24-pair interaction model was 0.686–0.702 based on 1000 bootstrap runs.

Expression quantitative trait loci analyses. To evaluate the biological functions of the identified
SNP pairs, we performed 2-way expression quantitative trait loci (eQTL) tests, which evaluated associations
between 1 identified SNP pair (2 SNPs) and 1 gene expression in the 4 target pathways. The linear modelbased AA9int approach was applied. As shown in Supplementary Table S5, there were 24 significant eQTL tests
with a P value < 1.1 × 10–8 (Bonferroni criteria = 0.05/4.5 × 106). The distribution of − log10-transformed P values
for the eQTL tests is shown in Supplementary Fig. S5. Among these 24 significant eQTL tests (Supplementary
Table S5), all of them involved 1 of the 4 top KLK3 SNPs (rs17632542, rs2569735, rs1058205, and rs174776), and
16 tests involved SNP pairs within the top 3144 pairs. One SNP in FHIT, rs995633, interacted with 2 KLK3 SNPs
(rs1058205 and rs2569735), which link to SLC25A21 expression. In addition, the genotype combinations of
rs7224135 (CAVIN1) + rs174776 (KLK3) had a significant effect on SRD5A2 expression (Supplementary Fig. S6,
P = 2.5 × 10–9). These promising eQTL results support that the KLK3 SNP pairs may have an impact on PCa
aggressiveness by altering specific gene expression.
Gene interaction network with KLK3.

For gene-level interactions, there were 6 common genes with > 50
SNP pairs from the top 3145 SNP pairs that interacted with KLK3 and were associated with PCa aggressiveness.
As shown in Fig. 5, The 6 most common gene–gene interaction pairs were KLK3-COL4A1: COL4A2, KLK3CDH13, KLK3-TGFBR3, KLK3-EGFR, KLK3-FGFR2, and KLK3-PRKCA. We applied the STRING database
(https://string-db.org/)21 to analyze the gene–gene (protein–protein) interaction network. We also added 2 genes
(FN1 and the androgen receptor [AR]) based on our literature review. Among the top 3145 pairs, there were 27
pairs for KLK3-FN1 and 4 pairs for KLK3-AR. This gene–gene interaction network supports the idea that the
majority of our identified SNP–SNP interactions are directly or indirectly linked with KLK3. KLK3 had a direct
link with FN1 and AR, which both link to EGFR. EGFR is also the hub for this gene–gene interaction network.
For pathway-level analyses, the summary of the within- or between-pathway interactions for the top 3145 SNP
pairs is shown in Supplementary Table S6. Among our 4 target pathways, the most common pathway-pathway
interactions are androgen-angiogenesis (1543 SNP pairs) and androgen-mitochondria (1138 SNP pairs) interactions. Among the 3145 SNP pairs, 98.6% were involved with KLK3 in the androgen pathway. This explains why
the androgen pathway is the hub for pathway–pathway interactions.

Discussion

Our study identified 3 KLK3 SNPs (rs17632542, rs62113212, and rs2569735) and 3145 SNP interaction pairs that
were associated with PCa aggressiveness. The KLK3 SNP rs17632542, which is in a strong LD with rs62113212,
had been previously identified in GWAS as being associated with several PCa-related outcomes, such as the
patient’s PSA level, PCa risk, and age at PCa diagnosis and the tumor’s volume, aggressiveness, and Gleason
score22. The SNP rs2569735 has been shown to influence miRNA functions23. The SNP rs2735839, which has a
strong LD with rs2569735, is associated with PCa a ggressiveness24.
The prostate is an androgen-dependent organ, and SNPs in genes involved in the androgen metabolism
pathway, such as KLK3, have been previously implicated in PCa risk and p
 rogression22,25. KLK3 is a proteincoding gene on chromosome 19q13.4, and its protein product, PSA, is a serine protease exclusively secreted by
the prostate gland into the seminal fluid, where it plays an important functional role in the normal physiology
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Figure 5.  KLK3 gene–gene interaction network based on common genes interacted with KLK3. KLK3 and AR
are in the androgen pathway. All other genes in the table are in the angiogenesis pathway. SNP single-nucleotide
polymorphism. The gene–gene interaction network plot was generated using the STRING software (https://
string-db.org/).
of the p
 rostate26. PSA is not normally secreted into the bloodstream; therefore, serum PSA levels are used for
screening, diagnosing, and prognosticating P
 Ca27.
Our results were consistent with previously published literature. As shown in Supplementary Table S7, our
literature review showed that the KLK3 individual SNPs rs17632542, rs2569735, and rs1058205 were significantly associated with PCa aggressiveness and PSA level. KLK3 was involved in 98.6% of the top 3145 SNP pairs
associated with PCa aggressiveness; the 4 KLK3 SNPs (rs17632542, rs2569735, rs1058205, and rs174776) contributed to 90.8% (2856 pairs) of the identified SNP pairs. Interestingly, the 2 most common SNPs (rs17632542
and rs2569735), which interacted with many other SNPs, also had significant individual effects. According to
the quality-controlled gene–gene (protein–protein) association network (Fig. 5), the majority of our identified
genes had a direct or indirect link with KLK3. In this network, FN1 and AR had a direct link with KLK3. Both
FN1 and AR are linked to EGFR, which is the hub for this gene–gene interaction network. KLK3 and AR are in
the androgen pathway, and FN1 and EGFR are in the angiogenesis pathway.
FN1 is known as a ubiquitous multifunctional glycoprotein and is involved in cell growth, migration, and
differentiation28. An 8-gene panel has reported FN1 to distinguish high-grade PCa from indolent PCa, with a
sensitivity of 93% and specificity of 70%29. AR is known to play a vital role in PCa development and progression,
and PCa cells rely on androgens for proliferation and s urvival30. KLK3 gene expression is regulated by AR through
androgen response elements in the promoter of PSA. Both FN1 and AR are regulated by miRNA-1207-3p in
PVT1, and these two genes are overexpressed in human PCa cell lines and tissues and are associated with PCa
aggressiveness31. We also reported that miR-3162-5p is associated with an rs1058205-T allele in KLK3 and can
regulate KLK3 and AR expression32. The bioinformatics analyses using STRING and GeneMANIA33 software
show the links between KLK3, FN1, and AR.
As shown in Fig. 5, the 6 most common genes/regions interacting with KLK3 are all in the angiogenesis pathway. KLK3 expression may decrease PCa aggressiveness by inhibiting a ngiogenesis34. We previously reported that
several angiogenesis genes influenced PCa aggressiveness35. Both COL4A1 and COL4A2 influence angiogenesis
and tumor growth. COL4A1 was associated with cell invasion and movement as a gene in the epithelial-to-mesenchymal (EMT) transition process, and COL4A1 gene expression has been associated with the Gleason score36.
COL4A2 provides a structural component for basement membranes, is known as an inhibitor of angiogenesis,
and has been considered as a biomarker for screening for benign prostatic hyperplasia37.
CDH13 is located on chromosome 16q24 and is a well-known tumor suppressor gene involved in cell–cell
adhesion. The expression of CDH13 has been associated with poor PCa prognosis and low proliferation rates
of prostate tumor c ells38. TGFBR3 is one of TGF-β receptors and is abundantly expressed in PCa cells. TGFBR3
is downregulated during the transition from benign to malignant and metastatic prostate tissues, especially in
bone metastases39. Several studies consistently report downregulation of TGFBR3 in prostate tumors, suggesting
that it has an important role as a tumor suppressor g ene40,41.
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KLK3 can attenuate the response to FGF2, an angiogenesis-stimulating factor that binds to FGFR2 and reduces
endothelial cell proliferation and migration, indicating FGF2 suppressive effect during m
 etastasis42. PRKCA is
a key negative regulator of the TGF-β pathway and is downregulated in PCa tumors. Cell migration, invasion,
and bone metastasis are suppressed by overexpression of PRKCA. Further, expression of PRKCA has been correlated with clinical variables, such as PSA levels, Gleason score, and metastasis status of patients with PCa39.
For the non-KLK3 SNP pairs, KPNA3, with 21 SNP pairs, was the most common gene, and there were 5
pairs for KPNA3-AR interaction. KPNA3 is one of the subunits of the nuclear pore complex and plays a role in
nuclear protein import43. In addition, the expression of KPNA3 was inversely associated with survival. Baker
et al. demonstrated that KPNA3 knockdown inhibited cell proliferation, migration, and invasion. KPNA3 may
regulate protein transfer to promote colorectal cancer growth, metastasis, and relapse43.
We identified one additional SNP pair (rs390993 in RIPK2 + rs473640 in NOS1) using the AA_Full model.
The receptor-interacting serine/threonine-protein kinase 2 (RIPK2) was one of the key regulators of the immune
response44. NO synthases (NOS) generate nitric oxide (NO), which can regulate tumorigenesis. Increased nitric
oxide level by NOS is cytotoxic to cancer c ells45. NOS1 downregulation reduced the growth of chemokine expressing fibroblasts and their ability to promote tumor formation in prostate cancer c ells46. Although these genes’ role
has not been studied in PCa aggressiveness, RIPK2 polymorphisms were associated with risk of gastric47 and
breast48 cancers. NOS1 polymorphisms were associated with the risk of various cancers, such as p
 ancreatic49,
glioma50, colorectal cancer, and melanoma51.
Our validated SNP–SNP interactions have been supported by both the protein–protein interaction network
and eQTL results. As shown in Supplementary Table S5 and Supplementary Fig. S6, SNP interactions between
CAVIN1 and KLK3 influenced SRD5A2 expression. CAVIN1 has been shown to reduce lymphangiogenesis and
angiogenesis52. As shown in Fig. 5, CAVIN1 links to KLK3 through EGFR and AR according to the protein–protein interaction network. SRD5A2 converts testosterone to dihydrotestosterone, which activates ARs53,54. SRD5A2
expression was significantly higher among patients with high-grade PCa vs. those with low-grade P
 Ca55,56. In our
previous study, we reported that the validated SNP–SNP interaction pairs of MMP16-EGFR, MMP16-ROBO1,
and MMP16-CSF1 were significantly associated with PCa aggressiveness and that EGFR is the hub of these
interactions13. We observed that MMP16, EGFR, ROBO1, and CSF1 interacted with KLK3 and were associated
with PCa aggressiveness. Among the top 3145 SNP pairs, 62 pairs were KLK3-EGFR interactions, 9 pairs were
KLK3-MMP16 interactions, 9 pairs were KLK3-ROBO1 interactions, and 1 pair was a KLK3-CSF1 interaction.
Both proteins form MMP16 and EGFR have been implicated in PCa. Several cancers that involve EGFR signaling often show an abnormally high expression of MMP1657. Although 2 genes (CDH13 and TGFBR3) do not
have a link to KLK3 according to the protein–protein interaction network (Fig. 5), several miRNAs (such as
miR_6731_5p, miR_8085, and miR_3919) contribute to the links between KLK3 and these 2 g enes58.
Importantly, our study demonstrated that SNP–SNP interactions could explain PCa aggressiveness better
than individual SNP effects focusing on genes from the 4 selected pathways. Our study also showed that the
2-stage AA9int + SIPI approach is a powerful tool for identifying and validating SNP–SNP interactions associated with a selected phenotype. The AA9int + SIPI approach is powerful because it allows genotype subgroups
with similar risk profiles or small sample sizes combined. Our risk classification system based on the model with
24 validated SNP interaction pairs is promising. Using this SNPint-PRS (score range 0–100), the prevalence of
aggressive PCa cases from our cohort was 49.8%, 21.9%, and 7.0% with top 1%, middle 50%, and bottom 1% risk
profiles, respectively. We observed that SNP pairs in the same cluster tended to be highly correlated. This may
explain why we identified > 9000 significant SNP pairs. By dropping the highly correlated pairs within a cluster,
we effectively reduced variable dimensions for building a multi-pair prediction model. Further biological studies
will be needed to distinguish driver or passenger effects for the identified SNP pairs.
For pathway-level interactions related to PCa aggressiveness, the most common interactions were involved
with the androgen pathway (such as KLK3), especially androgen-angiogenesis (49.1%) and androgen-mitochondria pathway interactions (36.2%, Supplementary Table S6). Angiogenesis is induced by overexpression of
angiogenesis-related genes, which are regulated by many factors, including elevated androgen l evels16. A previous
study reported interaction between the regulation of angiogenesis-related genes and androgen59. Further, clinical
therapies targeting genes involved in the androgen and angiogenesis pathways suggest an interaction between
these 2 pathways17. In addition, recent studies have reported that androgen-related genes regulate mitochondrial
respiration in PCa cells18. Androgen treatment leads to an increase in the activity of several metabolic pathways,
including mitochondrial biogenesis and a ctivity60. However, androgen repression in PCa cells decreases mitochondrial activity and cell p
 roliferation18.
There are some limitations to our study. First, there is no external validation for the S NPint-PRS, and the
identified SNP–SNP interactions may be influenced by the significance of their constituent SNP individual
effects. Further analyses using large-scale studies will be needed for further verification. Second, it is challenging
to identify causal SNP pairs because some SNP pairs are highly correlated, especially for SNP pairs in the same
cluster. The downstream gene expression analyses or laboratory experiments will be needed to identify causal
SNP pairs with biological functions. Lastly, this study only evaluated SNP–SNP interactions for the selected 4
pathways, so evaluation of SNP–SNP interactions in other pathways or genes will be required to gain a thorough
understanding of the complicated gene–gene interactions associated with PCa prognosis.
In summary, this study demonstrates that KLK3 alone and interactions between KLK3 and other identified
genes play an important role in PCa aggressiveness. As shown in Fig. 5, KLK3 directly links with FN1 and AR,
and other genes are indirectly linked to KLK3 through these two genes. The KLK3 SNP–SNP interactions can
explain PCa aggressiveness better than individual SNPs. The identified SNP–SNP and gene–gene interactions
may provide valuable insights for identifying downstream genes that affect PCa progression. Genetic markers,
such as a panel of SNPs, are excellent predictive biomarkers as they remain unchanged during patients’ lifetime.
Thus, the SNP-based scores can be a useful tool used for early prediction of future PCa progression, not just early
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detection when PCa progression already occurs. In addition, SNPs are tissue-independent, and can be measured
non-invasively, so our SNP interaction-based PRS of PCa aggressiveness may be used clinically for disease classification and treatment guidance. Further investigation of the biological functions of the identified genes and
additional validation of this prediction model is needed.

Methods

Study population. This study included 20 270 PCa cases (22.6% of which were aggressive PCa) with European ancestry from 21 studies within the Collaborative Oncological Gene-Environment Study (COGS) in the
Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL)
Consortium. Details of the PRACTICAL Consortium study have been previously r eported20. PCa aggressiveness was defined as Gleason score ≥ 8, PSA level > 100 ng/mL, distant disease stage at diagnosis, or PCa-related
death. Ethnic groups were defined based on ~ 37,000 uncorrelated markers that passed quality control, including ~ 1000 that were selected as ancestry informative markers. Half of the cases from each study site were randomly assigned to discovery and validation sets (10,135 cases in each set).
Selection of genes and SNPs. We evaluated 8587 SNPs from 2122 genes within 4 pathways: the angio-

genesis-, mitochondria-, miRNA-, and androgen metabolism-related pathways. These pathways were selected
based on our previous studies13,35, the literature, and PCa GWAS. These SNPs were genotyped on a custom
iCOGS Illumina array (Illumina, San Diego, CA, USA) using blood DNA samples. SNPs were excluded if they
had a call rate < 95%, a call rate < 99% with minor allele frequency (MAF) < 5%, MAF < 1%, or if their genotype
frequencies departed from Hardy–Weinberg equilibrium at P < 1 × 10−12.

Statistical analyses. The effects of individual SNPs and 2-way SNP–SNP interactions on the outcome of
PCa aggressiveness were evaluated. The analyses were conducted separately for the discovery set and validation
set. To control for population substructure, the principal component analysis was performed. All models were
adjusted for the study site and the first 6 principal components of population stratification as suggested by the
PRACTICAL study20. For evaluating individual SNP effects, we considered three different inheritance modes:
dominant [D], recessive [R], and additive [A] modes, which were assigned based on the minor allele. Logistic
models were applied, and the best mode with the lowest P value was selected for each SNP.
We assessed 2-way SNP–SNP interactions. LD among all testing SNPs was examined based on r2. In order
to avoid multicollinearity in modeling, we tested correlations of neighborhood SNPs within 100 kilobases using
PLINK. SNPs with a strong LD of r2 > 0.8 were excluded from interaction analyses. A total of 5345 SNPs with a
MAF > 0.05 and no strong LD (r2 < 0.8) were included for SNP–SNP interaction analyses.
For SNP–SNP interactions, we applied the conventional AA_Full approach using PLINK in the discovery, validation and combined sets. In addition, we applied a powerful 2-stage AA9int + SIPI approach to search intensively
for SNP–SNP interactions associated with PCa aggressiveness. The AA9int approach, which treats all SNPs as
having an additive inheritance mode (additive–additive patterns [AA_]), tested 9 interaction patterns of pairwise
SNP–SNP interactions associated with an outcome10. The SIPI approach is an extended version of AA9int and
tests 45 biologically meaningful SNP–SNP interaction patterns by considering 2 more inheritance modes (dominant and recessive)9. Thus, SIPI’s test patterns include additive–additive (AA_), dominant–dominant (DD_),
dominant–recessive (DR_), recessive–dominant (RD_), and recessive–recessive (RR_) models. The AA9int and
SIPI models are composed of the full-interaction model (both main effects plus interaction), the models with
1 main effect and 1 interaction, and models with interaction only. The corresponding patterns’ names are Full,
M1_int, M2_int, or Int_, which represent various types of interactions with 3, 2, 2, and 1 term(s) in the statistical
model equation, respectively (see the equations below). For easy interpretation, these SIPI interaction patterns
can be shown as the 3 × 3 table with a heat table format using the plot3by3 function in the SIPI R package9,10.
Full : SNP1 + SNP2 + SNP1 × SNP2
M1_int : SNP1 + SNP1 × SNP2
M2_int : SNP2 + SNP1 × SNP2
Int_ : SNP1 × SNP2
The SNP pairs with binary modes (such as DD and RR) categorize the subjects into 2, 3, and 4 distinct risk
groups for interaction-only, main + interaction, and full-interaction models, respectively. For AA models, the
coding for an SNP with the additive mode is 0, 1, or 2 for the number of the target alleles, so the coding of the
interaction term of 2 additive SNPs (SNP1 × SNP2) is 0, 1, 2, or 4. The details of these 2 methods were described
previously9,10. We considered the original (0, 1, and 2 for the number of minor alleles) and reverse coding directions. For the binary outcome of PCa aggressiveness, the logistic-based AA9int was applied, and the best model
was selected based on the lowest BIC value for each SNP pair. For a large-scale study, the 2-stage AA9int + SIPI
approach is suggested. For performing AA9int and SIPI analyses, we used the ‘parAA9int’ and ‘parSIPI’ functions
in the SIPI R package in this study. There are four related functions in the SIPI R package: SIPI, parSIPI, AA9int,
and parAA9int. The parSIPI and parAA9int functions are parallel computing versions of SIPI and AA9int, which
can be used for large-scale studies. We applied logistic-based AA9int and SIPI. The details of SIPI and AA9int
parameter settings are listed in the SIPI R package manual. The SIPI R package and its manual are freely available
for download at GitHub (https://github.com/LinHuiyi/SIPI).
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As shown in Fig. 1, the 2-stage AA9int + SIPI approach was applied in the discovery set to evaluate 1.4 × 107
candidate SNP pairs associated with PCa aggressiveness. Promising SNP pairs with P < 0.001 in the screening
stage were further evaluated using the SIPI approach. The SNP pairs in the discovery set with P < 0.001 were
further validated in the validation set. We defined significant results using P < 0.001 in both the discovery and
validation sets and a P value less than the significance level of Bonferroni correction (P < 5.8 × 10–6 [= 0.05/8587
SNPs] for the individual SNP effects and P < 3.5 × 10–9 [= 0.05/1.4 × 107 pairs] for interactions in the combined
set). As it is well-known that Bonferroni correction is too stringent, we also used a P < 1 × 10–5 as the cutoff to
select promising SNP–SNP interaction pairs. For testing whether an SNP interaction pair performed better
than their composite individual SNP effects, we also compared the P-value of an SNP pair with P values of their
composite individual SNP effects for SNP pairs with an interaction-only pattern. For SNP pairs with > 1 terms,
the stepwise selection within a pair was applied. The methods used for S NPint-PRS, comparison of model performance, eQTL analyses, and the gene–gene interaction networks are listed in Supplementary Methods. All
analyses were based on 2-sided tests.
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